menu
    • menu
    [{"orgOrder":0,"company":"Exogenus Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2025","type":"Collaboration","leadProduct":"Exo-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Exogenus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exogenus Therapeutics \/ Exogenus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Exogenus Therapeutics \/ Exogenus Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Exogenus Therapeutics

    Menu

    Exogenus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exogenus Therapeutics

                            Portugal arrow
                            PharmaVenue
                            Not Confirmed

                            Exogenus Therapeutics

                            Portugal arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exo-101

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Exogenus Therapeutics Partners with Lonza to Develop GMP Process for Exo-101 Manufacturing

                            Details : The collaboration aims to develop Exo-101, Exogenus’ exosome-based lead candidate. It is derived from immunologically privileged cells from umbilical cord blood, being evaluating for fibrosis.

                            Product Name : Exo-101

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            March 11, 2025

                            Lead Product(s) : Exo-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth